Seeking Alpha

Cantor raises price target on Celldex

  • Cantor Fitzgerald follows Leerink in hiking the price target on Celldex Therapeutics (CLDX) after the stock's recent move higher.
  • Once the shares rose above Cantor's previous target ($24), analyst Mara Goldstein knew just what to do: "Shares have experienced strength of late [and] we like CLDX's pipeline and the opportunity for continued valuation expansion based on catalyst events. Using a risk-adjusted revenue calculation of each [pipeline] candidate, plus the value of technology, early-stage assets, and cash, we see upside to $39."
  • The new target represents a 19% upside from Monday's close.
From other sites
Comments (1)
  • Guest 9X9
    , contributor
    Comments (46) | Send Message
    I think the horse had already left the barn, Mara.....
    24 Sep 2013, 08:51 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs